Book early and save up to $500

# Tumor Models

## 23-25 July 2013 | Boston

Sharpen Clinical Predictions
Optimize Translational Decision-Making
Transform Pipeline Performance

Revere Hotel, Boston Common

## Benefits of Attending

- Understand how the leading drug developers are using preclinical tumor models that are **superior in predicting clinical efficacy**
- Learn how to generate tumor models that will lead to **better decision making moving into the clinic**
- Discover how to use novel tumor models to get a **broader, more accurate view of your drug activity**
- Overcome the limitations of current models and **bring molecules into the clinic with more confidence**
- Meet with world renowned experts in industry and academia to **expand your personal network of tumor model professionals**

## Workshops: 23rd July 2013

**A) Modeling and Simulation for Effective Translation of PK/PD, Efficacy and Toxicity**
**Jay Mettetal**, Senior Scientist, **Millennium Pharmaceuticals**

**B) Optimizing your Current Tumor Imaging Capabilities to more Accurately Visualize the Impact of a Drug on a Tumor**
**Dai Fukumura**, Associate Professor of Radiation Oncology, **Massachusetts General Hospital**

**C) Exploring Patient-Derived Tumor Xenografts to Enhance Data Sets and Improve Efficacy Predictions**
**John Tentler**, Associate Professor, **University of Colorado**

## Speaking Companies

Pfizer, Genentech, Eisai, Novartis, ImmunoGen, Inc., Merck, University of California San Diego, National Institutes of Health, EMD Serono, Verastem, AstraZeneca, MedImmune, Momenta, Sanofi, Roche

## Keynote Presentation From:

**Napoleone Ferrara**
Distinguished Professor
**UC San Diego**

## 23 Expert Speakers Including:

**Anderson Clark**
Director of *in vivo* Pharmacology
**EMD Serono**

**Richard Gregory**
Laboratory Head
**Sanofi**

**Frank Gibbons**
Senior Scientist
**AstraZeneca**

**George Naumov**
Senior Research Biologist
**Merck**

**Ching Ching Leow**
Senior Scientist
**MedImmune**

**Birgit Schultes**
Senior Research Director
**Momenta Pharmaceuticals**

**Dhaval Shah**
Senior Scientist
**Pfizer**

**Terri Van Dyke**
Head of Cancer Pathways & Mechanisms
**NIH**

**Li Yu**
Research Director
**Roche**

**Tel:** +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
**www.tumor-models.com**

hansonwade

# Tumor Models | Boston | 23rd – 25th July 2013

## Access the Right Models and Design the Future of Your Oncology Pipeline with Confidence

**Tumor Models** will arm you with the capability needed to build and interpret **the very best preclinical oncology models**.

This groundbreaking, pharma-focussed meeting is rich with data on the leading edge preclinical models that are **better predictors of clinical efficacy**. Decide which molecules to move forward into the clinic **with the highest possible confidence**, using data that's **more reflective of clinical performance**. World renowned experts will be sharing their secrets for designing and using tumor models. You'll leave with the latest techniques to humanize your models and **make better translational decisions**. Decisions that will **slash the current attrition rate in your oncology pipeline** and ultimately lead to **effective therapeutics for patients**.

**Tumor Models** gives you timely access to the industry intelligence, combined with academic insight, that you can't find anywhere else. **Cutting edge data, exclusive research, opportunities to collaborate** – this meeting is a must for those committed to bringing successful cancer drugs into the clinic.

**How will Tumor Models help you develop and apply better preclinical models?**

- **Listen to groundbreaking keynote presentations on current tumor models** from research leaders in the field, including **Napoleone Ferrara** and **Terri Van Dyke**
- **Overcome challenges of preclinical model development** using examples of patient-derived tumor models from **EMD Serono**, **MedImmune**, **Verastem** and **Millennium Pharmaceuticals**
- Determine how **Novartis** overcome the limitations of genetically engineered mouse models **to better investigate tumor development**
- Learn how **Pfizer** are using heterotopic tumor models **to allow a more realistic assessment of drug efficacy in patients**
- Understand the approach **Genentech** takes in developing **clinically relevant models for metastatic cancers**
- Explore how **Roche** select an appropriate molecular entity as early as possible **to minimize later stage attrition**
- Engage in interactive panel discussions addressing the issues of preclinical data interpretation with **Eisai**, **ImmunoGen** and **Jounce Therapeutics**, amongst others.

## Who Should Attend?

Attendees will leave with a list of practical ideas to optimize their current tumor models. Meet and network with cancer researchers, academics and drug developers to ensure maximum quality of discussions and add valuable contacts to your network.

**This meeting is for:**

- **Drug developers** who are looking to optimize current tumor models and explore practical alternatives to ensure the effective translation of preclinical data into a clinical setting
- **Small biotechs & model providers** looking to showcase their optimized and alternative tumor model platforms
- **Academics and researchers** looking to learn more about the most up to date tumor models, together with alternate animal systems. It's also a great opportunity to look for collaborations and funding
- **CRO's** specializing in preclinical drug development and oncology

LinkedIn Search groups for: **Tumour Models** to join the online community.

## Keynote Speaker:

**Napoleone Ferrara**
Distinguished Professor
**UC San Diego**

Napoleone is credited with identifying the human VEGF gene and describing its proangiogenic properties, which formed the basis for the development of Genentech's bevacizumab. In 2013 he was awarded the $3 million Breakthrough Prize in Life Sciences for his work.

## Hear what Previous Hanson Wade Attendees have to say

"I got much more out of this conference than from the recent AACR conference"
**AstraZeneca**

"Very valuable and useful information. One of the best meetings I've ever attended."
**Millennium**

"It exceeded my expectations. The talks were high quality and the interaction among participants was excellent."
**Genentech**

"Very good scientific content and stimulating discussions"
**Metabolon**

"Excellent presentations covering a good spread of approaches and technologies"
**MedImmune**

"The focused meetings are very useful. It brings the right people together"
**Zymeworks**

**Tel:** +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
**www.tumor-models.com**

hansonwade

# Tumor Models | Boston | 23rd – 25th July 2013

Keynote Session | Panel Session | Networking Session

## Day 1 — 24th July 2013

8.00 **Registration, Coffee & Networking**

8.55 **Chair's Opening Remarks**
**Terri Van Dyke**, Head of Cancer Pathways & Mechanisms, **NIH**

9.00 **Preclinical Tumor Models – How Predictive Are They?**

- A detailed overview of the challenges the pharmaceutical industry face with tumor models
- Overcoming issues related to translating data from animal models into the clinic
- Strategies to drive forward the field of tumor models and improve clinical outcome

**Napoleone Ferrara**, Distinguished Professor, **UC San Diego**
*Plus extended Q&A session – What issues do we, the industry, need to address at Tumor Models*

10.00 **Speed Networking**
A revolutionary and highly valued way to meet fellow attendees in a 60 minute session. Bring lots of business cards!

11.00 **Morning Refreshments**

### Building Tumor Models That Are as Predictive as Possible of Clinical Outcome

11.30 **Placing the Diversity of Different Tumor Models in the Context of Drug Development in the Pharmaceutical Industry**

- Reviewing the retrospective literature regarding the predictivity of xenograft models to identify the gaps
- Placing the appropriate model in the discovery context using cell line models with known genetics as an example
- Case study: using patient-derived xenograft models for indication verification in phase 2 decisions

**Anderson Clark**, Director of *In Vivo* Pharmacology, **EMD Serono**

12.00 **Overcoming the Limitations of GEM models to Better Investigate Tumor Development – A Pharma Perspective**

- Assessing the current GEM models used in drug development and identifying those that induce tumors resembling human cancer
- Understanding how best to model the tumor microenvironment and co-morbidities using GEM models
- Dealing with the expense and limited numbers of mice to necessitate dose-finding and scheduling experiments

**Brant Firestone**, Senior Investigator, **Novartis**

12.30 **Lunch**

1.30 **Using Patient-Derived Explants in Cancer Biologic Drug Discovery to Better Mimic Tumor Activity in Humans**

- Understanding how patient-derived explant models (PTX) show a genetic and pathological heterogeneity that leads to greater clinical relevance
- Reviewing internal studies using PTX that have contributed to the development of personalized oncology treatments
- Using PTX to recapitulate the molecular diversity of patient tumors

**Ching Ching Leow**, Senior Scientist, **MedImmune**

2.00 **Preclinical Learning and Relevance to Clinical Development for More Confidence in Candidate Selection**

- Demonstrating proof of concept to ultimately achieve a breakthrough therapy
- Looking at a sharper focus on which preclinical studies have addressed questions that are critical to development
- Selecting an appropriate molecular entity as early as possible to minimize later stage attrition

**Li Yu**, Research Director, **Roche**

2.30 **Is There Really a Lack of Predictive Preclinical Models, or Do We Just Not Apply and Interpret them in an Appropriate Manner?**

Drug developers have a broad panel of preclinical tumor models, but applying and interpreting the data in an appropriate manner presents a number of challenges. This panel will support you with study design and interpretation.

**Jan Pinkas, ImmunoGen; Jennifer Michaelson, Jounce Therapeutics; Kuan-Chun Huang, Eisai; Thomas Seyfried, Boston College**

3.00 **Afternoon Refreshments**

### Novel Tumor Models and Their Use to Build Confidence In Selected Molecules

3.30 **Building Multi-Scale Models that Integrate *In Vivo* and *In Vitro* Results, Ensuring Consistency and Confidence**

- Understanding how integrating *in vitro* and *in vivo* results can build confidence in the molecules brought into the clinic
- Using multi-scale models to predict outcomes for clinical dosing schedules
- Identifying the appropriate methods to reconcile the differences between *in vitro* and *in vivo* data

**Vihren Kolev**, Scientist, **Verastem**

4.00 **Using Orthotopic Tumor Models to Strengthen the Ability of Selecting Appropriate Molecules**

- Exploring orthotopic models as a way to minimize the limitations of traditional xenografts
- Using heterotopic tumor models to allow a more realistic assessment of drug efficacy in patients
- Addressing the common challenges of orthotopic platforms, including price and skill set required

**Pasquale Cirone**, Postdoctoral Fellow, **Pfizer**

4.30 **Alternative Models for Metastasis and their Use in Predicting the most Appropriate Therapies in the Clinic**

- Addressing the current lack of appropriate animal models for cancer progression
- Introducing new mouse models of progressive melanoma to enhance confidence of molecules to be brought forward
- Studying mechanisms associated with drug resistance of recurrent BRAF, NRAS and non-BRAF/NRAS melanomas

**Glenn Merlino**, Head of Cancer Modeling, **NIH**

5.00 **Chair's Closing Remarks**

5.15 **Poster Session**

**Tel:** +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
**www.tumor-models.com**

hansonwade

Keynote Session | Panel Session | Networking Session

## Day 2 — 25th July 2013

8.00 **Registration, Coffee & Networking**

8.55 **Chair's Opening Remarks**
**Terri Van Dyke**, Head of Cancer Pathways & Mechanisms, NIH

### Applying and Interpreting Tumor Models to Ensure their Relevance to Clinical Tumor Subtypes

9.00 **Improving Current Strategies for Validating Animal Models of Cancer**
- Studying the mechanisms of cancer etiology at a variety of levels
- Using GEMMS to examine cause/effect relationships in initiation and progression of disease within the natural microenvironment
- Identifying studies that have produced highly penetrant preclinical cancer models useful for translational studies

**Terri Van Dyke**, Head of Cancer Pathways & Mechanisms, NIH

9.30 **Hammer or Scalpel? How Expectations of Biology Impact Preclinical-to-Clinical**
- Determining the underlying biological mechanism of action of anticancer agents
- Understanding the differences in response rates caused by host biology (mouse vs. human)
- Asking the right preclinical questions to ensure effective translation into a clinical setting

**Arijit Chakravarti**, Senior Scientist, Millennium Pharmaceuticals

10.00 **Complementary Orthotopic and GEM Models to Better Predict and Understand Efficacy in the Clinic**
- Using preclinical tumor models to better predict efficacy in humans
- Dealing with cancer heterogeneity using orthotopic models to better answer preclinical questions
- Addressing common questions related to dosing and dose optimization for clinical trials

**Birgit Schultes**, Senior Director of Translational Research, Momenta Pharmaceuticals

10.30 **Mastermind Session**

This session will provide a highly effective and energizing format for you to access the knowledge of fellow attendees whilst collaboratively discussing topics and questions raised from the meeting.

11.15 **Morning Refreshments**

11.45 **Overcoming PK/PD Barriers to Link Drug Levels with the Biological Effects in a Tumor**
- Using tumor models to monitor interactions of a drug and target in the clinic
- Establishing *in vivo* systems that are quantifiable and measured over a particular time course
- Performing PK/PD experiments to link drug levels to the biological effects in a tumor

**Frank Gibbons**, Senior Scientist, AstraZeneca

12.15 **Case Study: Development of a Clinically Relevant Model of Metastatic Colorectal Cancer**
- Looking at existing colorectal cancer models and their disadvantages
- Generating a novel colorectal cancer model that overcomes many of the current limitations
- Using the model for investigating routes of metastatic spread to target organs

**Kevin Leong**, Scientist, Genentech

12.45 **Lunch**

1.45 **Identifying and Validating Biomarkers by Modeling Human Tumor Growth between Animals and Humans**
- Overcoming common challenges associated with translating data into the clinic
- Using methods that address the issues associated with traditional biomarker selection
- Finding the best approaches from selection to efficient biomarker translation

**George Naumov**, Senior Research Biologist, Merck

2.15 **Panel Discussion: How Can We Deal With The Low Availability of Funds and Inadequate Amounts of Therapeutics in Preclinical Oncology Development**

The costs incurred by cancer drugs failing in the clinic are skyrocketing. This panel will address how the problem can be tackled by the recent improvements in tumor models.

**Jianguo Ma**, EMD Serono; **Richard Gregory**, Sanofi; **Sharon McGonigle**, Eisai

2.45 **Afternoon Refreshments**

3.15 **Case Study: Systems Pharmacology Approaches to Preclinically Identify and Test Predictive Biomarkers for Clinical Application**
- Describing challenges inherent in translating drug distribution properties from mouse to humans
- Discussing the use of sensitivity analyses to identify biomarkers that modulate response
- Case study of translating tumor microenvironment-based biomarkers into assays intended for clinical application

**Jonathan Fitzgerald**, Proof of Concept Director, Merrimack Pharmaceuticals

3.45 **Using a Platform PBPK Model to Characterize Plasma and Tissue Disposition of Monoclonal Antibodies in Preclinical Species and Humans**
- Developing a PBPK model capable of characterizing plasma and tissue PK of nonspecific monoclonal antibodies
- Evaluating the scale up potential of the model by charecterizing mouse, rat, monkey and human plasma PK simultaneously
- Benefits of using PBPK for preclinical studies to make informed decisions

**Dhaval Shah**, Senior Scientist, Pfizer

4.15 **Chair's Closing Remarks**

**Tel:** +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
**www.tumor-models.com**

# Tumor Models | Boston | 23rd – 25th July 2013

## Workshop A: Modeling and Simulation for Effective Translation of PK/PD, Efficacy and Toxicity

**Date: 23rd July 2013**
**Time: 8.30am – 11.30am**

Preclinical questions surrounding PK/PD, efficacy and toxicity are critical determinants of drug activity. In addition to the search for better tumor models, there remains an effort to improve methods for optimizing efficacy predictions and determining PD drivers of toxicity. A higher level of understanding of such parameters is vital to developing improved cancer therapeutics in the clinic.

During this workshop, you will understand how to overcome **the barriers for accurate PD predictions of toxicity**. You will identify the models that produce highly predictive data sets, **especially in preparation for a First-In-Human trial** (FIH).

Attend this workshop to:

- Understand the best methods for effective modelling and use of PD drivers **to mitigate differences in host biology**
- Learn about effective translational modelling of xenograft tumor **efficacy for more predictive data**
- **Choose the right preclinical questions** to effectively translate data into recommendations for the clinic

Attendees will leave this workshop knowing **how to better address the preclinical questions associated with PD predictions of toxicity and dosing schedule.**

### Workshop leader

**Jay Mettetal**
Senior Scientist
**Millennium Pharmaceuticals**

Jay has led over 20 modeling and simulation projects and has received a number of awards for organizing a team to model antibody-drug-conjugates. Previously, Jay has used mechanistic models to answer questions about project feasibility, target selection, compound optimization and population stratification. Jay's work also includes implementing mechanism based PK/PD models and has developed tumor penetration models for oncology. His work has spearheaded efforts to model new technologies, combining modeling output with market analysis for target selection.

## Workshop B: Optimizing Your Current Tumor Imaging Capabilities to more Accurately Visualize the Impact of a Drug on a Tumor in Your Preclinical Model

**Date: 23rd July 2013**
**Time: 12.00pm – 3.00pm**

Using non-invasive imaging techniques on your tumor models allows you to greatly improve the predictive value of preclinical cancer models. Yet key challenges surrounding the technology and its use need to be overcome for the true potential of tumor imaging to be realized.

This workshop will allow you to make huge strides in unravelling the complex biology of tumors through accurate biomarker identification and appropriate technology.

Attend this workshop to:

- Learn how to more accurately visualize the impact of your drug on tumor activity to **minimize costly attrition in your oncology pipeline**
- **Identify and validate true imaging biomarkers** that are highly indicative of disease state
- Understand how to adopt the most up to date imaging systems and **develop more sophisticated targeted imaging protocols**

Attendees will leave with the practical capabilities to enhance their current preclinical imaging capabilities **ensuring that the most accurate predictions are made moving through the clinic.**

### Workshop leader

**Dai Fukumura**
Associate Professor
**Massachusetts General Hospital**

Dai is an internationally recognized expert in imaging, angiogenesis, and vascular and tumour biology. Dai is an associate professor and the deputy director of the Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School. The overall goal of the Steele Laboratory is to develop a fundamental and quantitative understanding of the integrative pathophysiology of tumour growth, angiogenesis, and metastasis, with the ultimate goal of improving prevention, detection, and treatment of tumours.

## Workshop C: Exploring Patient-derived Tumor Xenografts to Enhance Data Sets and Improve Efficacy Predictions

**Date: 23rd July 2013**
**Time: 3.30pm – 6.30pm**

Progress in oncology drug development has been slowed by a lack of predictive preclinical models that reliably predict clinical activity of novel compounds in cancer patients. Recent increases in the usage of patient-derived tumor xenografts have greatly enhanced efficacy predictions, drug safety and biomarker validation moving into the clinic. This workshop will address some of the novel approaches using patient derived xenograft models, together with how they can be used to overcome common issues with traditional systems.

Attend to:

- Receive an update on the most innovate patient-derived models available, **together with how to integrate them into your preclinical protocols**
- Learn about cutting edge case studies of where patient-derived tumor xenografts used **to predict drug efficacy**
- Hear an in-depth description about how these models can be used **for biomarker development and future applications**

Attendees will leave knowing how to make the most of the newest and most exciting tumor models that will lead **to better translational decision making.**

### Workshop leader

**John Tentler**
Associate Professor
**University of Colorado**

After receiving his Ph.D. in Molecular and Cellular Biochemistry from Loyola University of Chicago, John was recruited to the University of Colorado Denver in 1995 as a post-doctoral fellow in the laboratory of Dr. Arthur Gutierrez-Hartmann, M.D., in the Division of Endocrinology, Metabolism and Diabetes. He was promoted to Instructor in 1998 and then to Assistant Professor in 2003 in the Department of Medicine. In September 2007, he joined the faculty of the Division of Medical Oncology.

**Tel:** +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
**www.tumor-models.com**

hansonwade

# Tumor Models | Boston | 23rd – 25th July 2013

## Speakers

**Arijit Chakravarti**
Senior Scientist
**Millennium Pharmaceuticals**

Arijit is a translational pharmacologist working in the oncology therapeutic area. His expertise include identifying mechanisms of action (MoA) of anticancer agents and extending MoA to xenografts via efficacy and PK/PD studies.

**Pasquale Cirone**
Postdoctoral Fellow
**Pfizer**

Pasquale has had a career discovering and characterizing drug targets and signalling cascades that are critical for drug discovery. Having worked in drug development for over a decade, Pasquale has specialities ranging from small molecule drug discovery to biologics.

**Anderson Clark**
Director of *in vivo* Pharmacology
**EMD Serono**

Anderson and his team support projects from early discovery through Phase 2 clinical trials with *in vivo* studies involving efficacy testing, biomarker analyses, combination treatments with standard-of-care agents and PK/PD modeling.

**Napoleone Ferrara**
Distinguished Professor
**UC San Diego**

Napoleone is credited with identifying the human VEGF gene and describing its proangiogenic properties, which formed the basis for the development of Genentech's bevacizumab. In 2013 he was awarded the $3 million Breakthrough Prize in Life Sciences for his work.

**Brant Firestone**
Senior Research Investigator
**Novartis**

Brant's work focuses on dealing with the challenges related to selecting the 'right' *in vivo* oncology pharmacology model. His work involves assessing various model systems in preclinical drug discovery.

**Jonathan Fitzgerald**
Proof of Concept Director
**Merrimack Pharmaceuticals**

Jonathan leads the pre-POC team for MM-398, liposomal irinotecan, charged with the identification and clinical implementation of mechanism-based diagnostic and combination strategies for improving the outcome of cancer patients.

**Frank Gibbons**
Senior Scientist
**AstraZeneca**

Frank is a member of several preclinical and clinical oncology project teams at AstraZeneca, where he is responsible for modeling preclinical PK and PK/PD/efficacy relationships, as well as prediction of human PK and dose.

**Richard Gregory**
Laboratory Head
**Sanofi**

Rick currently leads a Target Identification and Validation laboratory within the Sanofi Oncology Division. His research efforts focus on the preclinical evaluation of potential therapeutic targets both in vitro and *in vivo* with a special interest in biologics.

**Kuan-chun Huang**
Scientist
**Eisai**

Kuan-chun is responsible for conducting a series of processes ranging from the discovery of innovative drug candidates through NDA filing and obtaining approval.

**Ching Ching Leow**
Senior Scientist
**MedImmune**

Ching joined MedImmune in 2006. She leads an *in vivo* pharmacology group and is the scientific lead on various oncology drug development teams. Her team conducts preclinical research in several areas of oncology research.

**Vihren Kolev**
Scientist
**Verastem**

Vihren currently works as a scientist at Verastem. His specialties include assay development, target validation and HTS. His previous positions were held at Massachusetts General Hospital.

**Kevin Leong**
Scientist
**Genentech**

Kevin is a cancer biologist with expertise in stem cell biology and metastasis. Following the completion of his postdoctoral training in the Department of Molecular Biology at Genentech, he transitioned to a Scientist role within Genentech. His laboratory currently focuses on colorectal cancer.

**Jianguo Ma**
Associate Director
**EMD Serono**

Jianguo received his doctorate degree in experimental therapy and pharmacology in Rotterdam Cancer Institute in 2006. Prior to joining EMD Serono, Jianguo previously worked *in In Vivo* Pharmacology at Vertex Pharmaceuticals. Between 2002-2005 he was Senior Investigator at Novartis.

**Sharon McGonigle**
Principle Scientist
**Eisai**

Sharon is a member of the Oncology Product Creation Unit (PCU) in the Discovery Biology Department. Sharon's role is to lead preclinical biology efforts on two programs, one of which is in early discovery and one that is currently in early clinical development.

**Glenn Merlino**
Head of Cancer Modeling
**NIH**

Glenn has served as the NIH Ombudsman for Animal Welfare, on the Editorial Board of Cancer Research, on the Steering Committee of the Center of Excellence in Integrative Cancer Biology and Genomics, and is an Executive Editor of Pigment Cell and Melanoma Research.

**Jennifer Michaelson**
Director of Research
**Jounce Therapeutics**

Jennifer's research programs have focused on monoclonal antibody targeting of TNF family member ligands and receptors for the treatment of cancer or autoimmune disease. Jennifer joined Jounce Therapeutics as Director of Research.

**George Naumov**
Senior Research Biologist
**Merck**

George is currently a Senior Research Biologist in Oncology at Merck. He was previously an Instructor in Surgery at Harvard Medical School and Children's Hospital Boston. George has a senior level, extensive professional experience in preclinical and translational oncology.

**Jan Pinkas**
Director
**ImmunoGen**

Jan is currently the Director of Pharmacology at ImmunoGen. Previously, he has worked in roles at Amgen and Genzyme. Jan was a postdoctoral fellow in Dr. Philip Leder's laboratory in the Genetics Department at Harvard Medical School.

**Thomas Seyfried**
Professor of Biology
**Boston College**

Thomas received his Ph.D in Genetics and Biochemistry in 1976. His research program focuses on gene environmental interactions related to complex diseases, such as epilepsy, autism, brain cancer and neurodegenerative diseases.

**Birgit Schultes**
Senior Research Director
**Momenta Pharmaceuticals**

Birgit heads a diverse group of *in vivo* and in vivo biologist and analytical scientists to transition development candidates through preclinical research into early clinical development. She is responsible for disease specific animal models and dosing optimization.

**Dhaval Shah**
Senior Scientist
**Pfizer**

Dhaval is a Senior Scientist in the PK/PD modeling and simulation group at Pfizer inc. He has developed PBPK models for both small and large molecules.

**Terri Van Dyke**
Head of Cancer Pathways & Mechanisms
**NIH**

Terry, a leader in the use and study of genetically modified mice to model human disease, serves as Chief of the Mouse Cancer Genetics Program and Director of the Center for Advanced Preclinical Research at the NCI.

**Li Yu**
Research Director
**Roche**

Li has worked as a Research Director and DMPK expert at Hoffmann-La Roche. She has contributed to many oncology programs from discovery to final registration including VELCADE, ZELBORAF and Obinutuzumab.

"Fantastic program and good atmosphere"

**Novo Nordisk**

**Tel: +1 212 537 5898** **Fax: +1 212 537 5898** **Email: info@hansonwade.com**

**www.tumor-models.com**

hansonwade

# Tumor Models | Boston | 23rd – 25th July 2013

## Sponsorship Opportunities

Miles Harley

If your organization needs to raise profile, promote products and services or develop new partnership opportunities in the Tumor Models sector, contact:

**tel:** +44 (0)20 3141 8797
**email:** mharley@hansonwade.com

## Working with Hanson Wade

When you work with Hanson Wade you work with a partner focused on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognized and respected by the industry. And our events are focused, leading edge and attended by people looking for knowledge before making decisions.

## Attendee Breakdown

### Expected Industry Breakdown of Attendees




### Expected Geographical Breakdown of Attendees




## Past Sponsor feedback

"Outstanding meeting with first class speakers. I learned a lot and I will certainly recommend the meeting to my colleagues"

**Sanofi Aventis**

"Very valuable and useful information. One of the best meetings I've ever attended."

**Millennium**

"It exceeded my expectations. The talks were high quality and the interaction among participants was excellent."

**Genentech**

"Excellent conference with good presentations and wonderful networking opportunities"

**ImmunoGen**

# Tumor Models | Boston | 23rd – 25th July 2013 | Priority Code: WEB

## Register

**Visit www.tumor-models.com**
**Tel:** +1 212 537 5898
**Fax:** +1 212 537 5898
**Email:** register@hansonwade.com

**Mail:**
Hanson Wade
304 Park Avenue South
11th Floor
New York, NY 10010

## Team Discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

## Venue and Accommodation

**Venue**
**Revere Hotel Boston Common**
200 Stuart Street, Boston, MA 02116
Tel: +1 617 482 1800

**Accommodation**
Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

## Event Prices

| Package | Register and pay before Friday 3rd May 2013* | Register and pay before Friday 7th June 2013* | Standard Price* |
|---|---|---|---|
| ☐ 2 day conference + 3 workshops | $3698 (save $500) | $3798 (save $400) | $3898 (save $300) |
| ☐ 2 day conference + 2 workshops | $3197 (save $400) | $3297 (save $300) | $3397 (save $200) |
| ☐ 2 day conference + 1 workshop | $2698 (save $300) | $2798 (save $200) | $2898 (save $100) |
| ☐ 2 day conference | $2199 (save $200) | $2299 (save $100) | $2399 |
| ☐ Workshops (each) | $599 | | |

**Please select your choice of workshop:** Workshop A ☐ Workshop B ☐ Workshop C ☐

* Discounted Not for Profit prices are available. Please visit www.tumor-models.com All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

## Delegate Details

Title: Forename: Surname:

Job Title: Company/Organization:

Email: Direct Manager:

Address:

Postcode:

Country: Direct Telephone:

Direct Fax: Mobile:

Switchboard: Signature: Date:

## Payment Details

Number of delegates: ☐ Amount: $ _____ Conference Documentation: ☐ Credit Card: ☐ Visa ☐ Mastercard ☐ Amex ☐

Card No: ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐ Valid from: ☐☐/☐☐ Expiry Date: ☐☐/☐☐

Cardholders name:

Signature: Date:

Card billing address:

**TERMS & CONDITIONS**

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Code: 3463

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

**Tel: +1 212 537 5898 Fax: +1 212 537 5898 Email: info@hansonwade.com**
**www.tumor-models.com**

hansonwade